Inflammatory Response Modulation by Low-Dose Anti-inflammatory Drugs Treatment in an In Vitro Osteoarthritis Cellular Model


Cite item

Full Text

Abstract

Background:Low-dose-medicine is based on the administration of low doses of biological regulators to restore the immunologic balance altered in the disease. Cytokines are pivotal regulators of cellular and tissue functions and impaired crosstalk, due to an imbalance between specific cytokines, it is fundamental in acute inflammation and diseases correlated to low-grade chronic inflammation. Osteoarthritis is the most prevalent arthritic disease and a leading cause of disability. In the treatment of muscle- skeletal pathologies, the therapeutic integration of conventional medicine with homotoxicology, or low-dose-medicine appears to be beneficial.

Objective:This study aims to get more insights into the role of inflammatory cytokines and chemokines during the development of osteoarthritis and to evaluate a possible blocking strategy using anti-inflammatory molecules, we resort to an in vitro experimental model using an established human chondrosarcoma cell line that underwent to a well known pro-inflammatory stimulus as bacterial lipopolysaccharide.

Methods:We tested the production of inflammatory-related cytokines and chemokines, and the efficacy of low-dose (LD) administration of anti-inflammatory compounds, namely IL-10 and anti-IL-1, to block inflammatory cellular pathways.

Results:Following an inflammatory insult, chondrocytes upregulated the expression of several pro-inflammatory cyto-/chemokines and this induction could be counteracted by LD IL-10 and anti-IL-1. We reported that these effects could be ascribed to an interfering effect of LD drugs with the NF-κB signaling.

Conclusion:Our results provided a good indication that LD drugs can be effective in inhibiting the inflammatory response in chondrocytes opening the way to new therapies for the treatment of diseases such as osteoarthritis.

About the authors

Marco Iuliano

Department of Medico-Surgical Sciences and Biotechnologies-Polo Pontino, Faculty of Pharmacy and Medicine, Sapienza University of Rome

Email: info@benthamscience.net

Valter Santilli

Department of Anatomical and Histological Sciences, Legal Medicine and Orthopedics, Faculty of Pharmacy and Medicine, Sapienza University of Rome

Email: info@benthamscience.net

Andrea Mineo

Department of Anatomical and Histological Sciences, Legal Medicine and Orthopedics, Faculty of Pharmacy and Medicine, Sapienza University of Rome

Email: info@benthamscience.net

Marco Paoloni

Department of Anatomical and Histological Sciences, Legal Medicine and Orthopedics, Faculty of Pharmacy and Medicine

Email: info@benthamscience.net

Paolo Rosa

Department of Medico-Surgical Sciences and Biotechnologies-Polo Pontino, Faculty of Pharmacy and Medicine, Sapienza University of Rome

Email: info@benthamscience.net

Giorgio Mangino

Department of Medico-Surgical Sciences and Biotechnologies-Polo Pontino, Faculty of Pharmacy and Medicine, Sapienza University of Rome

Email: info@benthamscience.net

Giovanna Romeo

Department of Medico-Surgical Sciences and Biotechnologies-Polo Pontino, Faculty of Pharmacy and Medicine, Sapienza University of Rome

Author for correspondence.
Email: info@benthamscience.net

References

  1. Robinson, W.H.; Lepus, C.M.; Wang, Q.; Raghu, H.; Mao, R.; Lindstrom, T.M.; Sokolove, J. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol., 2016, 12(10), 580-592. doi: 10.1038/nrrheum.2016.136 PMID: 27539668
  2. Mabey, T.; Honsawek, S. Cytokines as biochemical markers for knee osteoarthritis. World J. Orthop., 2015, 6(1), 95-105. doi: 10.5312/wjo.v6.i1.95 PMID: 25621214
  3. Kapoor, M.; Martel-Pelletier, J.; Lajeunesse, D.; Pelletier, J.P.; Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol., 2011, 7(1), 33-42. doi: 10.1038/nrrheum.2010.196 PMID: 21119608
  4. Aman, Z.S.; DePhillipo, N.N.; Familiari, F.; Dickens, J.F.; LaPrade, R.F.; Dekker, T.J. Acute intervention with selective interleukin-1 inhibitor therapy may reduce the progression of posttraumatic osteoarthritis of the knee: A systematic review of current evidence. Arthroscopy, 2022, 38(8), 2543-2556. doi: 10.1016/j.arthro.2022.02.009 PMID: 35189307
  5. Li, M.; Li, H.; Ran, X.; Yin, H.; Luo, X.; Chen, Z. Effects of adenovirus-mediated knockdown of IRAK4 on synovitis in the osteoarthritis rabbit model. Arthritis Res. Ther., 2021, 23(1), 294. doi: 10.1186/s13075-021-02684-8 PMID: 34863246
  6. Paoloni, M.; Agostini, F.; Bernasconi, S.; Bona, G.; Cisari, C.; Fioranelli, M.; Invernizzi, M.; Madeo, A.; Matucci-Cerinic, M.; Migliore, A.; Quirino, N.; Ventura, C.; Viganò, R.; Bernetti, A. Information survey on the use of complementary and alternative medicine. Medicina, 2022, 58(1), 125. doi: 10.3390/medicina58010125 PMID: 35056433
  7. Mancini, F.; Milardi, D.; Carfagna, P.; Grande, G.; Miranda, V.; De Cicco, N.A.; Ricciardi, D.; Pontecorvi, A.; Marana, R.; De Cicco Nardone, F. Low-dose SKA progesterone and interleukin-10 modulate the inflammatory pathway in endometriotic cell lines. Int. Immunopharmacol., 2018, 55, 223-230. doi: 10.1016/j.intimp.2017.12.008 PMID: 29272819
  8. Castiglioni, S.; Miranda, V.; Cazzaniga, A.; Campanella, M.; Nichelatti, M.; Andena, M.; Maier, J. Femtograms of interferon-γ suffice to modulate the behavior of jurkat cells: A new light in immunomodulation. Int. J. Mol. Sci., 2017, 18(12), 2715. doi: 10.3390/ijms18122715 PMID: 29244717
  9. Radice, E.; Miranda, V.; Bellone, G. Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. Int. Immunopharmacol., 2014, 19(1), 66-73. doi: 10.1016/j.intimp.2013.12.011 PMID: 24369312
  10. Gariboldi, S.; Palazzo, M.; Zanobbio, L.; Dusio, G.F.; Mauro, V.; Solimene, U.; Cardani, D.; Mantovani, M.; Rumio, C. Low dose oral administration of cytokines for treatment of allergic asthma. Pulm. Pharmacol. Ther., 2009, 22(6), 497-510. doi: 10.1016/j.pupt.2009.05.002 PMID: 19464382
  11. Dugina, J.L.; Petrov, V.I.; Babayeva, A.R.; Martyushev-Poklad, A.V.; Tcherevkova, E.V.; Epstein, O.I.; Sergeeva, S.A. A randomized, open-label, comparative, 6- month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis. Int. J. Tissue React., 2005, 27(1), 15-21. PMID: 15847101
  12. Peshekhonova, L.K.; Chernov, Y.N.; Barsukova, N.A.; Peshekhonov, D.V. Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome. Bull. Exp. Biol. Med., 2009, 148(3), 468-469. doi: 10.1007/s10517-010-0738-1 PMID: 20396714
  13. Cardani, D.; Dusio, G.F.; Luchini, P.; Sciarabba, M.; Solimene, U.; Rumio, C. Oral administration of interleukin-10 and anti-il-1 antibody ameliorates experimental intestinal inflammation. Gastroenterol. Res., 2013, 6(4), 124-133. doi: 10.4021/gr556w PMID: 27785242
  14. Martin-Martin, L.S.; Giovannangeli, F.; Bizzi, E.; Massafra, U.; Ballanti, E.; Cassol, M.; Migliore, A. An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. Drug Des. Devel. Ther., 2017, 11, 985-994. doi: 10.2147/DDDT.S118298 PMID: 28408798
  15. Blasi, E.; Barluzzi, R.; Bocchini, V.; Mazzolla, R.; Bistoni, F. Immortalization of murine microglial cells by a v-raf / v-myc carrying retrovirus. J. Neuroimmunol., 1990, 27(2-3), 229-237. doi: 10.1016/0165-5728(90)90073-V PMID: 2110186
  16. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods, 2001, 25(4), 402-408. doi: 10.1006/meth.2001.1262 PMID: 11846609
  17. Iuliano, M.; Mangino, G.; Chiantore, M.V.; Zangrillo, M.S.; Accardi, R.; Tommasino, M.; Fiorucci, G.; Romeo, G. Human Papillomavirus E6 and E7 oncoproteins affect the cell microenvironment by classical secretion and extracellular vesicles delivery of inflammatory mediators. Cytokine, 2018, 106, 182-189. doi: 10.1016/j.cyto.2017.11.003 PMID: 29137858
  18. Xie, J.; Lotoski, L.C.; Chooniedass, R.; Su, R.C.; Simons, F.E.R.; Liem, J.; Becker, A.B.; Uzonna, J.; HayGlass, K.T. Elevated antigen-driven IL-9 responses are prominent in peanut allergic humans. PLoS One, 2012, 7(10), e45377. doi: 10.1371/journal.pone.0045377 PMID: 23071516
  19. Boudot, A.; Kerdivel, G.; Habauzit, D.; Eeckhoute, J.; Le Dily, F.; Flouriot, G.; Samson, M.; Pakdel, F. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One, 2011, 6(6), e20898. doi: 10.1371/journal.pone.0020898 PMID: 21695171
  20. Arndt, S.; Landthaler, M.; Zimmermann, J.L.; Unger, P.; Wacker, E.; Shimizu, T.; Li, Y.F.; Morfill, G.E.; Bosserhoff, A.K.; Karrer, S. Effects of cold atmospheric plasma (CAP) on ß-defensins, inflammatory cytokines, and apoptosis-related molecules in keratinocytes in vitro and in vivo. PLoS One, 2015, 10(3), e0120041. doi: 10.1371/journal.pone.0120041 PMID: 25768736
  21. Cho, Y.S.; Kim, K.N.; Shim, J.H. Effects of cellular 11β-hydroxysteroid dehydrogenase 1 on lps-induced inflammatory responses in synovial cell line, SW982. Immune Netw., 2017, 17(3), 171-178. doi: 10.4110/in.2017.17.3.171 PMID: 28680378
  22. Nennig, S.E.; Schank, J.R. The role of NFkB in drug addiction: Beyond inflammation. Alcohol Alcohol., 2017, 52(2), 172-179. doi: 10.1093/alcalc/agw098 PMID: 28043969
  23. Magnani, M.; Crinelli, R.; Bianchi, M.; Antonelli, A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr. Drug Targets, 2000, 1(4), 387-399. doi: 10.2174/1389450003349056 PMID: 11467077
  24. Mangino, G.; Famiglietti, M.; Capone, C.; Veroni, C.; Percario, Z.A.; Leone, S.; Fiorucci, G.; Lülf, S.; Romeo, G.; Agresti, C.; Persichini, T.; Geyer, M.; Affabris, E. HIV-1 myristoylated nef treatment of murine microglial cells activates inducible nitric oxide synthase, NO2 production and neurotoxic activity. PLoS One, 2015, 10(6), e0130189. doi: 10.1371/journal.pone.0130189 PMID: 26066624
  25. Dhabhar, F.S. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol. Res., 2014, 58(2-3), 193-210. doi: 10.1007/s12026-014-8517-0 PMID: 24798553
  26. Raphael, I.; Nalawade, S.; Eagar, T.N.; Forsthuber, T.G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine, 2015, 74(1), 5-17. doi: 10.1016/j.cyto.2014.09.011 PMID: 25458968
  27. Appay, V.; Rowland-Jones, S.L. RANTES: A versatile and controversial chemokine. Trends Immunol., 2001, 22(2), 83-87. doi: 10.1016/S1471-4906(00)01812-3 PMID: 11286708
  28. Daly, C.; Rollins, B.J. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation, 2003, 10(3-4), 247-257. doi: 10.1080/mic.10.3-4.247.257 PMID: 12851642
  29. Iida, N.; Grotendorst, G.R. Cloning and sequencing of a new gro transcript from activated human monocytes: Expression in leukocytes and wound tissue. Mol. Cell. Biol., 1990, 10(10), 5596-5599. PMID: 2078213
  30. Marcu, K.B.; Otero, M.; Olivotto, E.; Borzi, R.M.; Goldring, M.B. NF-kappaB signaling: Multiple angles to target OA. Curr. Drug Targets, 2010, 11(5), 599-613. doi: 10.2174/138945010791011938 PMID: 20199390
  31. Bondeson, J.; Blom, A.B.; Wainwright, S.; Hughes, C.; Caterson, B.; van den Berg, W.B. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum., 2010, 62(3), 647-657. doi: 10.1002/art.27290 PMID: 20187160
  32. Fendrick, A.M.; Greenberg, B.P. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. Osteopath. Med. Prim. Care, 2009, 3(1), 1. doi: 10.1186/1750-4732-3-1 PMID: 19126235
  33. Liu, S.; Deng, Z.; Chen, K.; Jian, S.; Zhou, F.; Yang, Y.; Fu, Z.; Xie, H.; Xiong, J.; Zhu, W. Cartilage tissue engineering: From proinflammatory and anti-inflammatory cytokines to osteoarthritis treatments (Review). Mol. Med. Rep., 2022, 25(3), 99. doi: 10.3892/mmr.2022.12615 PMID: 35088882
  34. Moss, K.L.; Jiang, Z.; Dodson, M.E.; Linardi, R.L.; Haughan, J.; Gale, A.L.; Grzybowski, C.; Engiles, J.E.; Stefanovski, D.; Robinson, M.A.; Ortved, K.F. Sustained interleukin-10 transgene expression following intra-articular AAV5-IL-10 administration to horses. Hum. Gene Ther., 2020, 31(1-2), 110-118. doi: 10.1089/hum.2019.195 PMID: 31773987
  35. Ortved, K.F.; Begum, L.; Stefanovski, D.; Nixon, A.J. AAV-mediated overexpression of IL-10 mitigates the inflammatory cascade in stimulated equine chondrocyte pellets. Curr. Gene Ther., 2018, 18(3), 171-179. doi: 10.2174/1566523218666180510165123 PMID: 29749312
  36. Schulze-Tanzil, G.; Zreiqat, H.; Sabat, R.; Kohl, B.; Halder, A.; Müller, R.; John, T. Interleukin-10 and articular cartilage: Experimental therapeutical approaches in cartilage disorders. Curr. Gene Ther., 2009, 9(4), 306-315. doi: 10.2174/156652309788921044 PMID: 19534651
  37. Behrendt, P.; Preusse-Prange, A.; Klüter, T.; Haake, M.; Rolauffs, B.; Grodzinsky, A.J.; Lippross, S.; Kurz, B. IL-10 reduces apoptosis and extracellular matrix degradation after injurious compression of mature articular cartilage. Osteoarthritis Cartilage, 2016, 24(11), 1981-1988. doi: 10.1016/j.joca.2016.06.016 PMID: 27349464
  38. Reitamo, S.; Remitz, A.; Tamai, K.; Uitto, J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J. Clin. Invest., 1994, 94(6), 2489-2492. doi: 10.1172/JCI117618 PMID: 7989607
  39. Salaffi, F.; Ciapetti, A.; Carotti, M. The sources of pain in osteoarthritis: A pathophysiological review. Reumatismo, 2014, 66(1), 57-71. doi: 10.4081/reumatismo.2014.766 PMID: 24938198
  40. Kwilasz, A.J.; Grace, P.M.; Serbedzija, P.; Maier, S.F.; Watkins, L.R. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology, 2015, 96(Pt A), 55-69. doi: 10.1016/j.neuropharm.2014.10.020

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers